Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance.
about
A multiple reaction monitoring (MRM) method to detect Bcr-Abl kinase activity in CML using a peptide biosensorNCK Associated Protein 1 Modulated by miRNA-214 Determines Vascular Smooth Muscle Cell Migration, Proliferation, and Neointima Hyperplasia.Structural basis for recognition and remodeling of the TBP:DNA:NC2 complex by Mot1.Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitorsMaximizing peptide identification events in proteomic workflows using data-dependent acquisition (DDA).Global Cell Proteome Profiling, Phospho-signaling and Quantitative Proteomics for Identification of New Biomarkers in Acute Myeloid Leukemia PatientsCross-species proteomics reveals specific modulation of signaling in cancer and stromal cells by phosphoinositide 3-kinase (PI3K) inhibitorsPhosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in Wildtype and Mutated FLT3 Acute Myeloid Leukemia (AML) CellsAnalytical challenges translating mass spectrometry-based phosphoproteomics from discovery to clinical applications.Phosphoproteomic Analysis of Cell-Based Resistance to BRAF Inhibitor Therapy in Melanoma.Empirical inference of circuitry and plasticity in a kinase signaling networkReduced-representation Phosphosignatures Measured by Quantitative Targeted MS Capture Cellular States and Enable Large-scale Comparison of Drug-induced PhenotypesmTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype.Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.Time-resolved luminescence detection of spleen tyrosine kinase activity through terbium sensitizationIs phosphoproteomics ready for clinical research?Integrated transcriptomic and proteomic analysis identifies protein kinase CK2 as a key signaling node in an inflammatory cytokine network in ovarian cancer cellsPhosphoproteomic analysis identifies activated MET-axis PI3K/AKT and MAPK/ERK in lapatinib-resistant cancer cell line.Environmental stress affects the activity of metabolic and growth factor signaling networks and induces autophagy markers in MCF7 breast cancer cellsA Timely Shift from Shotgun to Targeted Proteomics and How It Can Be Groundbreaking for Cancer Research.Approaches for measuring signalling plasticity in the context of resistance to targeted cancer therapies.Role of phosphoproteomics in the development of personalized cancer therapies.Proteogenomics approaches for studying cancer biology and their potential in the identification of acute myeloid leukemia biomarkers.Label-Free Phosphoproteomic Approach for Kinase Signaling Analysis.Impact of phosphoproteomics in the translation of kinase-targeted therapies.Polyamine production is downstream and upstream of oncogenic PI3K signalling and contributes to tumour cell growth.Phosphoproteomics-Based Profiling of Kinase Activities in Cancer Cells.Statistical detection of quantitative protein biomarkers provides insights into signaling networks deregulated in acute myeloid leukemia.Kinase-substrate enrichment analysis provides insights into the heterogeneity of signaling pathway activation in leukemia cells.PHLDA1 Mediates Drug Resistance in Receptor Tyrosine Kinase-Driven Cancer.Factors Secreted by Cancer-Associated Fibroblasts that Sustain Cancer Stem Properties in Head and Neck Squamous Carcinoma Cells as Potential Therapeutic Targets
P2860
Q28486280-BD4F4F33-29DE-41C3-AF5F-76F17DB393C9Q29871102-5E44BDA6-F4CD-499C-AEB4-A12D8A873662Q30278870-E7890E7F-EAEE-4DC5-B554-0BDD6BDDE877Q30620482-19ADFBAE-9928-4955-B819-DB161C8621A1Q30652771-428471ED-2C95-4B10-992A-796C319927D0Q33555287-D6852EB1-A023-44F4-9D1E-D7101B25AD2AQ33718705-E343D5B9-D245-41C0-801A-F55889BF3594Q33882022-DD9F02F8-DCF2-45B3-8C99-5D7B62DE963AQ34604043-F1CC87DD-1A07-4B0F-A0B1-5CFE7DB1DC67Q35609071-C61FC1B4-6965-4491-9FDC-FCB657787C02Q35796180-4EF2729C-011C-44C2-A56C-B98101A17A92Q35935148-A3101DFC-925C-43EC-A98A-4A49C16954FBQ36110081-2DFD8930-97F8-401D-829E-44014219EAADQ36544778-C4B14103-55EC-41D9-BB58-6DE57CA896A4Q36784324-696F0274-4531-429F-9714-BBFD8181856DQ36799469-6B55712A-3A76-4165-B7EF-378FEE280289Q37085845-D8C53129-7190-4507-8CEE-20C96F909394Q37361549-243AEB22-1EDD-4089-BD88-B7F2190DCCA4Q37623642-9DF2D3A5-7B38-4DE0-8A41-4E77441A7DC7Q37651691-773EE475-0C69-4B04-8BF3-1E141160CC56Q38238607-DBEAC71F-42DC-4040-AE09-92D48FE67D17Q38285510-AF0A98F8-92C4-4FD1-A4B9-38696F92EDF0Q38660073-BA3B4DF3-54AF-410D-842C-3EA614DD5384Q38668703-20A85697-3168-4E20-9A60-7D45A4ED368FQ38989188-D0B48A84-4135-4101-9C63-F1E5E59A2A0FQ44469802-3E2F67AA-C43C-4B39-B772-BD3C16B9DA18Q49979433-E4D644D9-6FBE-440A-BF01-8C2B0AB43DFBQ51039769-F52C0970-1ED6-488F-9FBD-FD228147F60EQ53114408-18237CDE-CFB5-4A94-9201-7484B0165576Q53705802-2B192B49-BA84-460E-9711-318E2AB49872Q58730362-6DADF2F9-703D-4E80-BF43-2A2D63694AAC
P2860
Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Phosphoproteomic analysis of l ...... and mechanisms of resistance.
@en
Phosphoproteomic analysis of l ...... and mechanisms of resistance.
@nl
type
label
Phosphoproteomic analysis of l ...... and mechanisms of resistance.
@en
Phosphoproteomic analysis of l ...... and mechanisms of resistance.
@nl
prefLabel
Phosphoproteomic analysis of l ...... and mechanisms of resistance.
@en
Phosphoproteomic analysis of l ...... and mechanisms of resistance.
@nl
P2860
P50
P356
P1476
Phosphoproteomic analysis of l ...... n and mechanisms of resistance
@en
P2093
Bart Vanhaesebroeck
Pedro R Cutillas
P2860
P304
P356
10.1074/MCP.M112.017483
P577
2012-04-29T00:00:00Z